Portable, high intensity isotopic neutron source provides increased experimental accuracy

Small portable, high intensity isotopic neutron source combines twelve curium-americium beryllium sources. This high intensity of neutrons, with a flux which slowly decreases at a known rate, provides for increased experimental accuracy

Relationship of Black Walnut Wood Color to Soil Properties and Site

This investigation is the first to provide information for any species on the magnitude of quantitative wood color differences between individual trees and between groups of trees at specified locations. It is also the first to report on the effects of specific environmental factors on wood color. Larger differences were found between black walnut (Juglans nigra L.) trees in heartwood luminance (lightness) than in dominant wavelength (hue) or purity (percentage of principal hue). Indiana-grown walnut heartwood had higher luminance than Missouri-grown. The relationship of heartwood color to soil properties was greater than it was either to tree age or to diameter-growth rate (rings per inch)

Experimental Pd II oscillator strengths and the palladium abundance in the HgMn-type star chi Lupi

Experimental oscillator strengths for 19 ultraviolet lines of Pd II have been derived from measurements of line intensities in calibrated Fourier transform spectra, combined with picosecond-pulse laser measurements of radiative lifetimes. Five of these 19 lines, in addition to other Pd nr lines, are present in Hubble Space Telescope/Goddard High-Resolution Spectrograph echelle spectra of the chemically peculiar HgMn star chi Lupi, yielding a palladium abundance of log (N-Pd) = +5.0, which is 3.3 dex above the solar abundance. Theoretical oscillator strengths have been calculated for all strong ultraviolet transitions associated with the lowest odd-parity configuration of Pd II

Tunneling between two Luttinger liquids with long range interaction

The non linear charge transfer through a tunnel junction between two Luttinger systems is studied for repulsive, finite range interaction between electrons on the same, V_{11}, and on different,V_{12}, sides of the junction. Features of the Coulomb blockade effect are observed if V_{12}=0. We predict a novel interaction induced enhancement of the current if V_{12}>0. When V_{12}=V_{11}, the current is suppressed at small bias, but the ``charging energy'', obtained from the asymptotic behavior at high bias voltage, vanishes.Comment: 4 pages, RevTeX, to be published in Physical Review B (Brief Report

Depleted circulatory complement-lysis inhibitor (CLI) in childhood cerebral malaria returns to normal with convalescence

BACKGROUND: Cerebral malaria (CM), is a life-threatening childhood malaria syndrome with high mortality. CM is associated with impaired consciousness and neurological damage. It is not fully understood, as yet, why some children develop CM. Presented here is an observation from longitudinal studies on CM in a paediatric cohort of children from a large, densely-populated and malaria holoendemic, sub-Saharan, West African metropolis. METHODS: Plasma samples were collected from a cohort of children with CM, severe malarial anaemia (SMA), uncomplicated malaria (UM), non-malaria positive healthy community controls (CC), and coma and anemic patients without malaria, as disease controls (DC). Proteomic two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry were used in a discovery cohort to identify plasma proteins that might be discriminatory among these clinical groups. The circulatory levels of identified proteins of interest were quantified by ELISA in a prospective validation cohort. RESULTS: The proteome analysis revealed differential abundance of circulatory complement-lysis inhibitor (CLI), also known as Clusterin (CLU). CLI circulatory level was low at hospital admission in all children presenting with CM and recovered to normal level during convalescence (p < 0.0001). At acute onset, circulatory level of CLI in the CM group significantly discriminates CM from the UM, SMA, DC and CC groups. CONCLUSIONS: The CLI circulatory level is low in all patients in the CM group at admission, but recovers through convalescence. The level of CLI at acute onset may be a specific discriminatory marker of CM. This work suggests that CLI may play a role in the pathophysiology of CM and may be useful in the diagnosis and follow-up of children presenting with CM

Variability in Proto-Planetary Nebulae: I. Light Curve Studies of 12 Carbon-Rich Objects

We have carried out long-term (14 years) V and R photometric monitoring of 12 carbon-rich proto-planetary nebulae. The light and color curves display variability in all of them. The light curves are complex and suggest multiple periods, changing periods, and/or changing amplitudes, which are attributed to pulsation. A dominant period has been determined for each and found to be in the range of ~150 d for the coolest (G8) to 35-40 d for the warmest (F3). A clear, linear inverse relationship has been found in the sample between the pulsation period and the effective temperature and also an inverse linear relationship between the amplitude of light variation and the effective temperature. These are consistent with the expectation for a pulsating post-AGB star evolving toward higher temperature at constant luminosity. The published spectral energy distributions and mid-infrared images show these objects to have cool (200 K), detached dust shells and published models imply that intensive mass loss ended a few thousand years ago. The detection of periods as long as 150 d in these requires a revision in the published post-AGB evolution models that couple the pulsation period to the mass loss rate and that assume that intensive mass loss ended when the pulsation period had decreased to 100 d. This revision will have the effect of extending the time scale for the early phases of post-AGB evolution. It appears that real time evolution in the pulsation periods of individual objects may be detectable on the time scale of two decades

Evolution of the Thrombolytic Treatment Window for Acute Ischemic Stroke

Ischemic stroke is a major cause of morbidity and mortality for which the only approved treatment in the acute setting is intravenous thrombolysis. The efficacy and safety of recombinant tissue plasminogen activator (rt-PA) have been firmly established within 3 h of symptom onset; however, few patients are eligible for treatment in this time window. Expanding the time for treatment has been challenging, but new evidence has demonstrated a modest statistical improvement in selected patients when rt-PA is administered within 4.5 h. This important finding hopefully will enable more patients to receive treatment and simultaneously provides an opportunity to reaffirm that the benefits of rt-PA diminish with time

The usage of Stromgren photometry in studies of Local Group Dwarf Spheroidal Galaxies - Application to Draco: a new catalogue of Draco members and a study of the metallicity distribution function and radial gradients

In this paper we demonstrate how Stromgren uvby photometry can be efficiently used to: 1. Identify red giant branch stars that are members in a dwarf spheroidal galaxy. 2. Derive age-independent metallicities for the same stars and quantify the associated errors. Stromgren uvby photometry in a 11 x 22 arcmin field centered on the Draco dwarf spheroidal galaxy was obtained using the Isaac Newton Telescope on La Palma. Members of the Draco dSph galaxy were identified using the surface gravity sensitive c_1 index which discriminates between red giant and dwarf stars. Thus enabling us to distinguish the (red giant branch) members of the dwarf spheroidal galaxy from the foreground dwarf stars in our galaxy. The method is evaluated through a comparison of our membership list with membership classifications in the literature based on radial velocities and proper motions. The metallicity sensitive m_1 index was used to derive individual and age-independent metallicities for the members of the Draco dSph galaxy. The derived metallicities are compared to studies based on high resolution spectroscopy and the agreement is found to be very good. We present metallicities for 169 members of the red giant branch in the Draco dwarf spheroidal galaxy (the largest sample to date). The metallicity distribution function for the Draco dSph galaxy shows a mean [Fe/H] = -1.74 dex with a spread of 0.24 dex. The correlation between metallicity and colour for the stars on the red giant branch is consistent with a dominant old, and coeval population. There is a possible spatial population gradient over the field with the most metal-rich stars being more centrally concentrated than the metal-poor stars.Comment: Accepted for publication in A&A. 26 pages, 27 figures (some at reduced resolution). High resolution version available at http://www.astro.lu.se/~daniel/draco/faria.p

Randomized assessment of imatinib in patients with acute ischaemic stroke treated with intravenous thrombolysis

BackgroundImatinib, a tyrosine kinase inhibitor, has been shown to restore bloodâ brain barrier integrity and reduce infarct size, haemorrhagic transformation and cerebral oedema in stroke models treated with tissue plasminogen activator. We evaluated the safety of imatinib, based on clinical and neuroradiological data, and its potential influence on neurological and functional outcomes.MethodsA phase II randomized trial was performed in patients with acute ischaemic stroke treated with intravenous thrombolysis. A total of 60 patients were randomly assigned to four groups [3 (active): 1 (control)]; the active treatment groups received oral imatinib for 6 days at three dose levels (400, 600 and 800 mg). Primary outcome was any adverse event; secondary outcomes were haemorrhagic transformation, cerebral oedema, neurological severity on the National Institutes of Health Stroke Scale (NIHSS) at 7 days and at 3 months and functional outcomes on the modified Rankin scale (mRS).ResultsFour serious adverse events were reported, which resulted in three deaths (one in the control group and two in the 400â mg dose group; one patient in the latter group did not receive active treatment and the other received two doses). Nonserious adverse events were mostly mild, resulting in full recovery. Imatinib ameliorated neurological outcomes with an improvement of 0.6 NIHSS points per 100 mg imatinib (P = 0.02). For the 800â mg group, the mean unadjusted and adjusted NIHSS improvements were 4 (P = 0.037) and 5 points (P = 0.012), respectively, versus controls. Functional independence (mRS 0â 2) increased by 18% versus controls (61 vs. 79; P = 0.296).ConclusionThis phase II study showed that imatinib is safe and tolerable and may reduce neurological disability in patients treated with intravenous thrombolysis after ischaemic stroke. A confirmatory randomized trial is currently underway.Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/136298/1/joim12576_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/136298/2/joim12576.pd

A randomised controlled trial of antiplatelet therapy in combination with Rt-PA thrombolysis in ischemic stroke: rationale and design of the ARTIS-Trial

<p>Abstract</p> <p>Background</p> <p>Thrombolysis with intravenous rt-PA is currently the only approved acute therapy for ischemic stroke. Re-occlusion after initial recanalization occurs in up to 34% in patients treated with rt-PA, probably caused by platelet activation. In acute myocardial infarction, the combination of thrombolysis and antiplatelet therapy leads to a greater reduction of mortality compared to thrombolysis alone. In patients with acute ischemic stroke, several studies showed that patients already on antiplatelet treatment prior to thrombolysis had an equal or even better outcome compared to patients without prior antiplatelet treatment, despite an increased risk of intracerebral bleeding. Based on the fear of intracerebral haemorrhage, current international guidelines recommend postponing antiplatelet therapy until 24 hours after thrombolysis. Remarkably, prior use of antiplatelet therapy is not a contra-indication for thrombolysis. We hypothesize that antiplatelet therapy in combination with rt-PA thrombolysis will improve outcome by enhancing fibrinolysis and preventing re-occlusion.</p> <p>Methods/Design</p> <p>ARTIS is a randomised multi-center controlled trial with blind endpoint assessment. Our objective is to investigate whether immediate addition of aspirin to rt-PA thrombolysis improves functional outcome in ischemic stroke. Patients with acute ischemic stroke eligible for rt-PA thrombolysis are randomised to receive 300 mg aspirin within 1.5 hours after start of thrombolysis or standard care, consisting of antiplatelet therapy after 24 hours. Primary outcome is poor functional health at 3 months follow-up (modified Rankin Scale 3 - 6).</p> <p>Discussion</p> <p>This is the first clinical trial investigating the combination of rt-PA and acute aspirin by means of a simple and cheap adjustment of current antiplatelet regimen. We expect the net benefit of improved functional outcome will overcome the possible slightly increased risk of intracerebral haemorrhage.</p> <p>Trial registration</p> <p>The Netherlands National Trial Register NTR822. The condensed rationale of the ARTIS-Trial has already been published in Cerebrovascular Diseases.</p